HCC Clinical Trials in Nanjing, Jiangsu
11 recruitingNanjing, Jiangsu, China
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb198 enrolled64 locationsNCT07291076
Recruiting
Phase 1Phase 2
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Huahui Health30 enrolled21 locationsNCT07547553
Recruiting
Phase 1
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
Unresectable Hepatocellular Carcinoma (HCC)Hepatoma
Suzhou Mednovo Yi Medical Technology Co., Ltd.40 enrolled8 locationsNCT07391839
Recruiting
Phase 2
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
HCC - Hepatocellular Carcinoma
Zhejiang Hisun Pharmaceutical Co. Ltd.75 enrolled1 locationNCT07310173
Recruiting
Phase 2
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Hepatocellular Carcinoma (HCC)
Abbisko Therapeutics Co, Ltd141 enrolled51 locationsNCT07327034
Recruiting
Not Applicable
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Nanjing Tianyinshan Hospital300 enrolled1 locationNCT06893887
Recruiting
Phase 2Phase 3
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
HCC
Zhejiang Raygene Pharmaceuticals Co., Ltd300 enrolled2 locationsNCT06844357
Recruiting
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without TACE for Advanced HCC with Vascular Invasions
Hepatocellular Carcinoma (HCC)
Zhongda Hospital1,200 enrolled1 locationNCT06881446
Recruiting
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without HAIC for Advanced HCC
Hepatocellular Carcinoma (HCC)
Zhongda Hospital900 enrolled1 locationNCT06881433
Recruiting
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
Hepatocellular Carcinoma (HCC)
Zhongda Hospital300 enrolled2 locationsNCT06876753
Recruiting
Phase 2
Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
Hepatocellular Carcinoma (HCC)Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation
The First Affiliated Hospital with Nanjing Medical University276 enrolled1 locationNCT06762782